文献速递骨软组织肉瘤与黑色素瘤

瑞戈非尼对比安慰剂及交叉后瑞戈非尼在晚期非脂肪细胞软组织肉瘤中的疗效与安全性

Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma.
PubMed 文献 · Eur J Cancer · 2018-06-11

81%安慰剂进展患者交叉接受瑞戈非尼,其中59%生长调节指数≥1.3。

要点

  • 瑞戈非尼较安慰剂显著延长非脂肪细胞软组织肉瘤患者的无进展生存。
  • 总生存无显著差异,部分因安慰剂组高交叉率(81%)及交叉后瑞戈非尼活性。
  • 延迟使用瑞戈非尼较早期使用无进展生存数值缩短但无统计学意义,不影响总生存。

核心结论

  • 瑞戈非尼在难治性非脂肪细胞软组织肉瘤中显示无进展生存获益,值得进一步临床研究。

研究设计与样本

  • REGOSARC为安慰剂对照二期试验,2013年6月至2014年12月纳入139例非脂肪细胞软组织肉瘤患者,中位随访32.4个月。

主要发现

  • 安慰剂组68例进展患者中55例(81%)交叉接受瑞戈非尼,其中59%(95%CI 45-71%)生长调节指数≥1.3。

临床怎么用

  • 对于难治性非脂肪细胞软组织肉瘤,瑞戈非尼可作为候选治疗选择,但需权衡无进展生存获益与总生存无显著改善。

局限性

  • 总生存分析受安慰剂组高交叉率影响,可能低估瑞戈非尼的总生存获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The placebo-controlled phase-2 REGOSARC trial demonstrated the efficacy of regorafenib in patients with leiomyosarcoma, synovial sarcoma and other non-adipocytic sarcoma but not in liposarcoma. Patients initially allocated to placebo were allowed to receive regorafenib after progression. We report here an updated analysis of the trial including evaluation of regorafenib activity after cross-over. METHODS: From June 2013 to December 2014, 139 patients were enrolled in the non-adipocytic sarcoma cohorts. Median follow-up is now 32.4 months. Benefit of regorafenib versus placebo in terms of progression-free survival (PFS) and overall survival (OS) from randomisation was estimated by hazard ratio (HR) in Cox models. In the placebo arm, intra-patient benefit of regorafenib after cross-over was evaluated by the growth modulation index (GMI) (GMI was here, for each patient, PFS after cross-over regorafenib divided by PFS with placebo). Furthermore, the activity of delayed (after cross-over) versus early (at study entry) regorafenib was evaluated by comparing PFS after cross-over to regorafenib to PFS after randomisation in the regorafenib arm. RESULTS: PFS benefit of regorafenib as compared to placebo was confirmed with longer follow-up (HR = 0.50; 95% CI: 0.35-0.71; p < .0001). OS was not statistically significant different (HR = 0.78; 0.54-1.12; p = .18). This finding may partially be explained by the fact that 55/68 patients who progressed on placebo (81%) received cross-over Regorafenib after progression: 59% of them had a GMI ≥ 1.3 (95% CI, 45-71%). Delayed start of regorafenib was associated with a statistically non-significant shorter PFS as compared to early treatment (HR = 1.21; 0.84-1.73; p = .30) without impact on OS. CONCLUSIONS: Observed PFS confirms that regorafenib warrants further clinical investigation in refractory non-adipocytic sarcomas.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Brodowicz T, Mir O, Wallet J, et al. Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. Eur J Cancer. 2018. PMID: 29902612. doi:10.1016/j.ejca.2018.05.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。